|
1.
|
|
10 p, 666.8 KB |
Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain
/
Arriola, Edurne (Hospital del Mar (Barcelona, Catalunya)) ;
García Gómez, Ramón (Hospital General Universitario Gregorio Marañón) ;
Diz Taín, Pilar (Hospital Universitario de León) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Martínez Aguillo, Maite (Complejo Hospitalario de Navarra) ;
Valdivia, Javier (Hospital Universitario Virgen de las Nieves (Granada)) ;
Paredes, Alfredo (Hospital de Donostia (Sant Sebastià, País Basc)) ;
Sánchez-Torres, José Miguel (Hospital Universitario de la Princesa (Madrid)) ;
Peralta Muñoz, Sergio (Hospital Universitari Sant Joan de Reus (Tarragona)) ;
Barneto Aranda, Isidoro (Hospital Universitario Reina Sofía (Córdoba, Espanya)) ;
Gutierrez, Vanesa (Hospital Regional Universitario Carlos Haya (Málaga)) ;
Andrade Santiago, Jesús Manuel (Hospital Virgen de la Salud (Toledo)) ;
Aparisi, Francisco (Hospital Virgen de los Lirios) ;
Isla, Dolores (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Ponce, Santiago (Hospital 12 de Octubre (Madrid)) ;
Vicente Baz, David (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ;
Artal, Ángel (Hospital Universitario Miguel Servet (Saragossa)) ;
Amador, Mariluz (AstraZeneca) ;
Provencio, Mariano (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Universitat Autònoma de Barcelona
Although the benefit of first-line epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs) over chemotherapy has been demonstrated in several clinical trials, data from clinical practice is lacking and the optimal EGFR TKI to be used remains unclear. [...]
2018 -  10.1186/s12885-018-4004-7
BMC Cancer, Vol. 18 Núm. 1 (30 2018) , p. 106
|
|
|
2.
|
|
6 p, 380.2 KB |
Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer : final results of a randomised phase 2 clinical trial
/
Gridelli, C. (S.G. Moscati Hospital) ;
Ciuleanu, Tudor Eliade (Institutui. Oncologic I. Chircuta) ;
Domine, M. (Fundacion Jimenez Diaz) ;
Szczesna, A. (Mazowieckie Centrum) ;
Bover, I. (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Cobo, M. (Instituto de Investigaciones Biomédicas (IBIMA)) ;
Kentepozidis, N. (251 General Airforce Hospital) ;
Zarogoulidis, K. (Papanikolaou General Hospital) ;
Kalofonos, C. (University Hospital of Patras) ;
Kazarnowisz, A. (Oddzial Onkologiiz Pododdziatem) ;
Korozan, M. (Hospicjum Dutkiewicza SAC) ;
de las Peñas, R (Hospital Provincial de Castellon) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Chella, A. (A.O.U. di Pisa Hospital) ;
Griesinger, F. (Pius Hospital) ;
Bournakis, E. (University Hospital "Aretaieion") ;
Sadjadian, P. (Johannes Wesling Klinikum) ;
Kotsakis, A. (University General Hospital of Larissa) ;
Chinet, T. (Hopital Ambroise Paré) ;
Syrigos, K.N. (General Hospital of Thoracic Diseases "Sotiria") ;
Correale, P. (University Hospital of Siena) ;
Gallou, C. (Vaxon-Biotech) ;
Jamet, J.M. (Vaxon-Biotech) ;
Vetsika, E.K. (University General Hospital of Heraklion) ;
Kosmatopoulos, K. (Vaxon-Biotech) ;
Georgoulias, V. (University General Hospital of Heraklion) ;
Universitat Autònoma de Barcelona
The cancer vaccine Vx-001, which targets the universal tumour antigen TElomerase Reverse Transcriptase (TERT), can mount specific Vx-001/TERT CD8 + cytotoxic T cells; this immune response is associated with improved overall survival (OS) in patients with advanced/metastatic non-small cell lung cancer (NSCLC). [...]
2020 - 10.1038/s41416-020-0785-y
British Journal of Cancer, Vol. 122 Núm. 10 (december 2020) , p. 1461-1466
|
|
|
3.
|
|
37 p, 420.1 KB |
Cabozantinib combination therapy for the treatment of solid tumors : a systematic review
/
Castellano, Daniel (Hospital Universitario 12 de Octubre (Madrid)) ;
Apolo, Andrea B. (Center for Cancer Research. National Cancer Institute. National Institutes of Health) ;
Porta, Camillo (Interdisciplinary Department of Medicine. University of Bari 'Aldo Moro') ;
Capdevila Castillón, Jaume (Vall d'Hebron Institut d'Oncologia) ;
Viteri, Santiago (Instituto Oncológico Dr. Rosell) ;
Rodriguez-Antona, Cristina (Centro Nacional de Investigaciones Oncológicas) ;
Martin, Lidia (Ipsen Pharma) ;
Maroto Rey, Pablo (Institut d'Investigació Biomèdica Sant Pau)
Background: Cabozantinib monotherapy is approved for the treatment of several types of solid tumors. Investigation into the use of cabozantinib combined with other therapies is increasing. To understand the evidence in this area, we performed a systematic review of cabozantinib combination therapy for the treatment of solid tumors in adults. [...]
2022 - 10.1177/17588359221108691
Therapeutic Advances in Medical Oncology, Vol. 14 (2022)
|
|
|
4.
|
|
14 p, 586.6 KB |
Comprehensive cross-platform comparison of methods for non-invasive EGFR mutation testing : results of the RING observational trial
/
Romero, Atocha (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Jantus-Lewintre, Eloisa (Universitat Politècnica de València) ;
García-Peláez, Beatriz (Hospital Universitari Dexeus (Barcelona, Catalunya)) ;
Royuela, Ana (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Insa, Amelia (Hospital Clínic Universitari (València)) ;
Cruz Castellanos, Patricia (Hospital Universitario La Paz (Madrid)) ;
Collazo-Lorduy, Ana (Hospital Universitario HM Sanchinarro (Madrid)) ;
Pérez Altozano, Javier (Hospital Virgen de los Lirios) ;
Vidal, Oscar Juan (Hospital Universitari i Politècnic La Fe (València)) ;
Diz Taín, P (Complejo Asistencial Universitario de León) ;
Cobo, Manuel (Hospital Regional Universitario de Málaga) ;
Hernández, Berta (Complejo Hospitalario de Navarra) ;
Vázquez Estevez, Sergio (Hospital Universitario Lucus Augusti (Lugo)) ;
Benítez, Gretel (Complejo Hospitalario Universitario Insular de Gran Canaria) ;
Guirado, Maria (Hospital General Universitario de Elche) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Bernabé, Reyes (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Ortega Granados, Ana Laura (Complejo Hospitalario de Jaén) ;
Blasco, Ana (Centro de Investigación Biomédica en Red de Cáncer) ;
Bosch-Barrera, J (Institut d'Investigació Biomèdica de Girona) ;
Jurado, Jose M. (Hospital Universitario San Cecilio (Granada)) ;
García González, Jorge (Hospital Clínico Universitario (Santiago de Compostela, Galícia)) ;
Viteri, Santiago (Instituto Oncológico Dr. Rosell. Hospital Universitario Dexeus. Grupo Quiron Salud) ;
Garcia Giron, Carlos (Hospital Universitario de Burgos) ;
Massuti, Bartomeu (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Lopez Martín, Ana (Hospital Universitario Severo Ochoa) ;
Rodriguez-Festa, Alejandro (Fundación de Investigación Biomédica del H.U. Puerta de Hierro Majadahonda) ;
Calabuig-Fariñas, Silvia (Universitat de València. Departament de Patologia) ;
Molina-Vila, Miguel Ángel (Hospital Universitari Dexeus (Barcelona, Catalunya)) ;
Provencio, Mariano (Hospital Universitario Puerta de Hierro Majadahonda (Madrid))
Several platforms for noninvasive EGFR testing are currently used in the clinical setting with sensitivities ranging from 30% to 100%. Prospective studies evaluating agreement and sources for discordant results remain lacking. [...]
2021 - 10.1002/1878-0261.12832
Molecular Oncology, Vol. 15 Núm. 1 (january 2021) , p. 43-56
|
|
|
5.
|
|
10 p, 616.7 KB |
Treatment strategy optimization for patients with non-small-cell lung cancer harboring EGFR mutation : a Delphi consensus
/
Isla, Dolores (Instituto de Investigación Sanitaria de Aragón) ;
De Castro Carpeño, Javier (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ;
García-Campelo, R. (Complejo Hospitalario Universitario de A Coruña) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Vicente, David (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ;
Juan, Óscar (Hospital Universitari i Politècnic La Fe (València))
Aim: To stablish a consensus on the treatment strategy for advanced non-small-cell lung cancer (aNSCLC) with epidermal growth factor receptor mutation (EGFRm) in Spain. Methods: After a systematic literature review, the scientific committee developed 33 statements in 4 fields: molecular diagnosis (10 items); histologic profile and patient clinical characteristics (7 items); first-line (1L) treatment in EGFRm aNSCLC (8 items); and subsequent-line treatment (8 items). [...]
2021 - 10.1007/s12094-020-02518-0
Clinical & Translational Oncology, Vol. 23 Núm. 7 (july 2021) , p. 1304-1313
|
|
|
6.
|
|
14 p, 445.0 KB |
Targeting HER2 in non-small-cell lung cancer (NSCLC) : a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations
/
Riudavets, M. (Department of Cancer Medicine. Gustave Roussy Cancer Campus) ;
Sullivan, Ivana (Institut d'Investigació Biomèdica Sant Pau) ;
Abdayem, P. (Department of Cancer Medicine. Gustave Roussy Cancer Campus) ;
Planchard, D. (Department of Cancer Medicine. Gustave Roussy Cancer Campus)
Non-small-cell lung cancer (NSCLC) harbouring HER2 alterations is now considered a distinct molecular subtype. The activation of HER2 in NSCLC occurs via three mechanisms, i. e. gene mutation (1%-4% of cases), gene amplification (2%-5%) and protein overexpression (2%-30%), with different prognostic and predictive outcomes. [...]
2021 - 10.1016/j.esmoop.2021.100260
ESMO open, Vol. 6 Núm. 5 (october 2021) , p. 100260
|
|
|
7.
|
|
16 p, 1.9 MB |
Epigenetic-smoking interaction reveals histologically heterogeneous effects of TRIM27 DNA methylation on overall survival among early-stage NSCLC patients
/
Ji, X. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ;
Lin, L. (Department of Environmental Health. Harvard T.H. Chan School of Public Health) ;
Shen, S. (China International Cooperation Center for Environment and Human Health. Nanjing Medical University) ;
Dong, X. (Department of Epidemiology and Biostatistics. School of Public Health. Southeast University) ;
Chen, C. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ;
Li, Y. (Department of Biostatistics. University of Michigan) ;
Zhu, Y. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ;
Huang, H. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ;
Chen, J. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ;
Chen, X. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ;
Wei, Liangmin (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ;
He, J. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ;
Duan, W. (Department of Bioinformatics. School of Biomedical Engineering and Informatics. Nanjing Medical University) ;
Su, L. (Department of Environmental Health. Harvard T.H. Chan School of Public Health) ;
Jiang, Y. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ;
Fan, J. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ;
Guan, J. (Department of Biostatistics. Center for Global Health. School of Public Health. Nanjing Medical University) ;
You, D. (Department of Environmental Health. Harvard T.H. Chan School of Public Health) ;
Shafer, A. (Harvard Medical School) ;
Bjaanæs, Maria Moksnes (Department of Cancer Genetics. Institute for Cancer Research. Oslo University Hospital) ;
Karlsson, A. (Division of Oncology and Pathology. Department of Clinical Sciences Lund and CREATE Health Strategic Center for Translational Cancer Research. Lund University) ;
Planck, M. (Division of Oncology and Pathology. Department of Clinical Sciences Lund and CREATE Health Strategic Center for Translational Cancer Research. Lund University) ;
Staaf, J. (Division of Oncology and Pathology. Department of Clinical Sciences Lund and CREATE Health Strategic Center for Translational Cancer Research. Lund University) ;
Helland, Å. (Institute of Clinical Medicine. University of Oslo) ;
Esteller, M. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Wei, Y. (China International Cooperation Center for Environment and Human Health. Nanjing Medical University) ;
Zhang, R. (China International Cooperation Center for Environment and Human Health. Nanjing Medical University) ;
Chen, F. (Jiangsu Key Lab of Cancer Biomarkers. Prevention and Treatment. Cancer Center. Collaborative Innovation Center for Cancer Personalized Medicine. Nanjing Medical University) ;
Christiani, David C (Harvard Medical School) ;
Universitat Autònoma de Barcelona
Tripartite motif containing 27 (TRIM27) is highly expressed in lung cancer, including non-small-cell lung cancer (NSCLC). Here, we profiled DNA methylation of lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) tumours from 613 early-stage NSCLC patients and evaluated associations between CpG methylation of TRIM27 and overall survival. [...]
2020 - 10.1002/1878-0261.12785
Molecular Oncology, Vol. 14 Núm. 11 (january 2020) , p. 2759-2774
|
|
|
8.
|
|
10 p, 2.7 MB |
A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer
/
Yamamoto, Nobuyuki (Wakayama Medical University. Third Department of Internal Medicine) ;
Hayashi, Hidetoshi (Kindai University Faculty of Medicine. Department of Medical Oncology) ;
Planchard, David (Institut Gustave Roussy (Villejuif, França)) ;
Morán, Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Gregorc, Vanesa (IRCCS Ospedale San Raffaele. Department of Oncology, Division of Experimental Medicine) ;
Dowell, Jonathan (University of Texas Southwestern Medical Center. Department of Internal Medicine) ;
Sakai, Hiroshi (Saitama Cancer Center. Department of Thoracic Oncology) ;
Yoh, Kiyotaka (National Cancer Center Hospital East. Department of Thoracic Oncology) ;
Nishio, Makoto (The Cancer Institute Hospital of the Japanese Foundation for Cancer Research. Department of Thoracic Medical Oncology) ;
Cortot, Alexis B. (Centre Hospitalier Universitaire de Lille. Thoracic Oncology Department) ;
Benhadji, Karim A. (Taiho Oncology, Inc. Department of Clinical Development) ;
Soni, Nital (Taiho Oncology, Inc. Department of Clinical Development) ;
Huang, Jinhong (Taiho Pharmaceutical Co., Ltd. Department of Pharmacovigilance) ;
Makris, Lukas (Stathmi, Inc, 125 Brownsburg Rd, New Hope, PA 18938 USA) ;
Cedrés, Susana (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
The online version of this article (10. 1007/s10637-020-00930-5) contains supplementary material, which is available to authorized users.
2020 - 10.1007/s10637-020-00930-5
Investigational New Drugs, Vol. 38 (april 2020) , p. 1588-1597
|
|
|
9.
|
|
6 p, 538.4 KB |
Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer
/
Bonanno, Laura (Medical Oncology 2 Unit, Istituto Oncologico Veneto I.R.C.C.S, Via Gattamelata 64, 35128 Padova, Italy) ;
Costa, Carla (Pangaea Biotech (Barcelona, Catalunya)) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Sanchez, Jose-Javier (Universidad Autónoma de Madrid) ;
Rodriguez, Ignacio (Universitat Autònoma de Barcelona. Institut Universitari Dexeus) ;
Giménez-Capitán, Ana (Pangaea Biotech (Barcelona, Catalunya)) ;
Molina-Vila, Miquel Angel (Pangaea Biotech (Barcelona, Catalunya)) ;
Vergnenegre, Alain (Hospital du Cluzeau, 23, rue Larey, Limoges, France) ;
Massuti, Bartomeu (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Favaretto, Adolfo (Medical Oncology 2 Unit, Istituto Oncologico Veneto I.R.C.C.S, Via Gattamelata 64, 35128 Padova, Italy) ;
Rugge, Massimo (Cytology and Pathology, Università degli Studi di Padova, Via Gabelli 61, Padova, Italy) ;
Pallares, Cinta (Institut d'Investigació Biomèdica Sant Pau) ;
Taron, Miquel (Universitat Autònoma de Barcelona. Institut Universitari Dexeus) ;
Rosell, Rafael (Universitat Autònoma de Barcelona. Institut Universitari Dexeus) ;
Universitat Autònoma de Barcelona
BRCA1 is a main component of homologous recombination and induces resistance to platinum in preclinical models. It has been studied as a potential predictive marker in lung cancer. Several proteins modulate the function of BRCA1. [...]
2016 - 10.1186/s12885-016-2339-5
BMC Cancer, Vol. 16 (may 2016)
|
|
|
10.
|
|
12 p, 2.4 MB |
MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC)
/
Casadevall Aguilar, David (Universitat Autònoma de Barcelona) ;
Gimeno, Javier (Hospital del Mar (Barcelona, Catalunya)) ;
Clavé, Sergi (Hospital del Mar (Barcelona, Catalunya)) ;
Taus, Álvaro (Hospital del Mar (Barcelona, Catalunya)) ;
Pijuan, Lara (Hospital del Mar (Barcelona, Catalunya)) ;
Arumí, Miriam (Hospital del Mar (Barcelona, Catalunya)) ;
Lorenzo, Marta (Hospital del Mar (Barcelona, Catalunya)) ;
Menéndez, Silvia (Hospital del Mar (Barcelona, Catalunya)) ;
Cañadas, Israel (Hospital del Mar (Barcelona, Catalunya)) ;
Albanell Mestres, Joan (Universitat Pompeu Fabra) ;
Serrano, Sergio (Hospital del Mar (Barcelona, Catalunya)) ;
Espinet i Solà, Blanca (Hospital del Mar (Barcelona, Catalunya)) ;
Salido, Marta (Hospital del Mar (Barcelona, Catalunya)) ;
Arriola, Edurne (University of Southampton)
We aimed to assess MET intratumoral heterogeneity and its potential impact on biomarker-based patient selection as well as potential surrogate biomarkers of MET activation. Our study included 120 patients with non-squamous Non-small-cell Lung Cancer (nsNSCLC), of which 47 were incorporated in tissue microarrays (TMA). [...]
2015 - 10.18632/oncotarget.3976
Oncotarget, Vol. 6, Núm. 18 (June 2015) , p. 16215-16226
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
